These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
560 related articles for article (PubMed ID: 17503894)
1. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Gennari L; Merlotti D; Valleggi F; Martini G; Nuti R Drugs Aging; 2007; 24(5):361-79. PubMed ID: 17503894 [TBL] [Abstract][Full Text] [Related]
2. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Maximov PY; Lee TM; Jordan VC Curr Clin Pharmacol; 2013 May; 8(2):135-55. PubMed ID: 23062036 [TBL] [Abstract][Full Text] [Related]
3. Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis. Gennari L Drugs Today (Barc); 2006 Jun; 42(6):355-67. PubMed ID: 16845439 [TBL] [Abstract][Full Text] [Related]
4. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development. Pinkerton JV; Goldstein SR Menopause; 2010; 17(3):642-53. PubMed ID: 20107426 [TBL] [Abstract][Full Text] [Related]
5. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies]. Maeda T; Ke HZ; Simmons H; Thompson D Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137 [TBL] [Abstract][Full Text] [Related]
6. Selective estrogen receptor modulators in clinical practice: a safety overview. Ellis AJ; Hendrick VM; Williams R; Komm BS Expert Opin Drug Saf; 2015 Jun; 14(6):921-34. PubMed ID: 25936229 [TBL] [Abstract][Full Text] [Related]
7. Use of SERMs for treatment in postmenopausal women. Pinkerton JV; Thomas S J Steroid Biochem Mol Biol; 2014 Jul; 142():142-54. PubMed ID: 24373794 [TBL] [Abstract][Full Text] [Related]
8. Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy. Gennari L Expert Opin Pharmacother; 2009 Sep; 10(13):2209-20. PubMed ID: 19640205 [TBL] [Abstract][Full Text] [Related]
9. Selective estrogen modulators in menopause. Gambacciani M Minerva Ginecol; 2013 Dec; 65(6):621-30. PubMed ID: 24346250 [TBL] [Abstract][Full Text] [Related]
10. Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene. Gennari L; Merlotti D; Nuti R Clin Interv Aging; 2010 Feb; 5():19-29. PubMed ID: 20169039 [TBL] [Abstract][Full Text] [Related]
11. Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women. Vogelvang TE; van der Mooren MJ; Mijatovic V; Kenemans P Drugs; 2006; 66(2):191-221. PubMed ID: 16451093 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. Palacios S Curr Med Res Opin; 2010 Jul; 26(7):1553-63. PubMed ID: 20429824 [TBL] [Abstract][Full Text] [Related]
13. Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. Lewiecki EM J Womens Health (Larchmt); 2009 Oct; 18(10):1615-26. PubMed ID: 19857095 [TBL] [Abstract][Full Text] [Related]
14. Bazedoxifene acetate: a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. Chines AA; Komm BS Drugs Today (Barc); 2009 Jul; 45(7):507-20. PubMed ID: 19834628 [TBL] [Abstract][Full Text] [Related]
15. Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis. de Villiers TJ Climacteric; 2010 Jun; 13(3):210-8. PubMed ID: 20184423 [TBL] [Abstract][Full Text] [Related]
16. SERMs: current status and future trends. Morello KC; Wurz GT; DeGregorio MW Crit Rev Oncol Hematol; 2002 Jul; 43(1):63-76. PubMed ID: 12098608 [TBL] [Abstract][Full Text] [Related]
17. The evolution of selective estrogen receptor modulators in osteoporosis therapy. Hadji P Climacteric; 2012 Dec; 15(6):513-23. PubMed ID: 22853318 [TBL] [Abstract][Full Text] [Related]